美女免费一级视频在线观看

    1. <form id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></form>
      <address id=BiMYPaeIF><nobr id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></nobr></address>

      Bristol Myers Squibb is yet another example of a Big Pharma company pledging a multibillion dollar investment in the U.S. as the Trump administration tries to woo drugmakers to boost their domestic operations. 

      The New Jersey-based pharma giant announced on Monday that it will be pouring $40 billion into the U.S. over the next five years, aiming to expand its research and manufacturing capabilities. 

      BMS CEO Christopher Boerner broke the news in an op-ed piece published by STAT News, where he noted that the company has “significant concerns” that some potential policies surfacing in Washington could threaten the health of Americans and the U.S. economy.

      He added that the move was made to ensure that Americans had access to healthcare and pharma products by the company. 

      The news comes after several other pharma companies announced significant investment into developing U.S. manufacturing plants in light of the potential 25% tariffs on pharmaceutical drugs placed by President Donald Trump. 

      There is currently a 10% tariff rate for general goods and 25% for some pharmaceutical products. 

      Late last month, Roche announced a $50 billion investment in U.S. manufacturing over the next five years. The same day, Regeneron announced plans to invest over $3 billion domestically.

      In late March, just days before the initial tariffs were unveiled, Johnson & Johnson announced it would spend $55 billion to develop new manufacturing facilities in the U.S. over the next four years.

      Eli Lilly recently announced it would spend $27 billion on U.S. manufacturing, commencing with building plans on four domestic manufacturing plants this year.

      Additionally, Pfizer CEO Albert Bourla said his company would be prepared to move its international manufacturing operations to the U.S. if tariffs are imposed.

      The news piggybacks on Trump’s latest executive order issued on Monday, which aims to reduce the amount of time pharmaceutical plants get approved in the U.S. to encourage more domestic manufacturing. 

      The executive order also directs the Food and Drug Administration to increase fees and inspection for foreign manufacturing plants, which may lead to more difficulty importing products. 

      “We don’t want to be buying our pharmaceuticals from other countries because if we’re in a war, we’re in a problem, we want to be able to make our own,” Trump said in a statement. 

      Boerner said that the company’s investments will be spread across the following areas — research and development, technology and manufacturing. 

      In his op-ed, Boerner added that investing in U.S. manufacturing will allow the company to monitor highly complex supply chains and bring manufacturing closer to the areas of research and development. 

      The plan, he said, will strengthen BMS’ presence across the country, “ramp up radiopharmaceutical manufacturing,” as well as invest in machine learning and artificial intelligence to increase the speed of innovation. 

      The news of BMS’ updated investment plan also comes shortly after the company let go of 516 workers in New Jersey. This is the third round of layoffs BMS has disclosed for Lawrenceville in 2025.

      This is part of the company’s cost-cutting, strategic reorganization initiative announced in February which aims to save $2 billion through 2027.